CAPR Falls 15.2% After Investor Alert on Class Action
Capricor Therapeutics (CAPR) fell 15.2% on Aug 24, 2026 after an investor alert highlighted a securities class action lawsuit tied to the company.
What Capricor announced
This wasn’t a traditional company press release about earnings or a product update — it was an “investor alert” distributed by Robbins LLP about Capricor.
According to the announcement, a securities class action has been filed on behalf of people and entities that bought or acquired Capricor securities during a stated class period.
The alert also emphasized a deadline for investors with significant losses to seek appointment as lead plaintiff.
The underlying allegations referenced by the alert center on Capricor’s lead product candidate, Deramiocel, and regulatory interactions described in the complaint, including a Biologics License Application (BLA) submission and an FDA Complete Response Letter requesting additional clinical data.
What it means for Capricor
An investor alert like this can put legal risk front-and-center for the market, even though it’s coming from a law firm rather than the company itself.
The filing and the push to recruit a lead plaintiff can keep attention on the allegations and the timeline described in the complaint, which could weigh on sentiment around Capricor’s regulatory narrative for Deramiocel.
More broadly, class action headlines can create an overhang because they raise questions about potential costs, management distraction, and how long the issue could linger.
How the stock reacted
CAPR sold off quickly and stayed lower through the close.
| Window | Move |
|---|---|
| 5 min | -13.3% |
| 10 min | -17.0% |
| 30 min | -17.5% |
| 1 hour | -15.2% |
| end of day | -15.2% |
On a market-adjusted basis, the stock’s move was -15.1% versus SPY the same day.